Moderna shares rise 177% on cancer vaccine news
Moderna and Merck announced the success of a personalized experimental vaccine for melanoma skin cancer. The vaccine showed positive results in phase three trials involving more than 1,100 patients. It achieved the primary goal of extending the time patients remained free of cancer recurrence and reducing the risk of metastasis to other parts of the body. These results came after the vaccine, based on mRNA technology and utilizing the immune therapy "Kitruda," demonstrated significant effectiveness compared to standard treatment, with notable improvements in survival outcomes and safety. This enhances the possibility of its being available soon after further studies and regulatory evaluations are completed.
Notice: This Is an AI-Generated Summary
Comments (0)